

Review Article

# Artificial Intelligence in Transfusion Medicine: Current Applications, Opportunities, and Challenges

**Ikemefula Oriaku<sup>1</sup>, Oluchi Okechukwu<sup>2</sup>, Obiageri Ihuarulam Okeoma<sup>3</sup>, Chidinma Gab-Obinna<sup>4</sup>, Jazuli Isyaku Bala<sup>5</sup>, Adeyinka Moyinoluwa Adejumobi<sup>6</sup>, Oluwabusayo Olufunke Awoyomi<sup>7</sup>**

<sup>1</sup>Department of Medical Laboratory Science, University of Nigeria, Enugu Campus, Nigeria

<sup>2</sup>Department of Laboratory Medicine, University of Vermont Medical Center, Burlington, VT, USA

<sup>3</sup>Department of Medical Laboratory Science, Trinity University Yaba, Yaba, Lagos, Nigeria

<sup>4</sup>Biomedical Laboratory Science Department, Kingston University London, London, United Kingdom

<sup>5</sup>Department of Hematology and Transfusion Medicine, Faculty of Clinical Sciences, Bayero University Kano, Aminu Kano Teaching Hospital, Kano, Nigeria

<sup>6</sup>Department of Data Science, Artificial Intelligence and Modelling, University of Hull, Hull, United Kingdom

<sup>7</sup>Department of Computer Science, University of Albany, Albany, NY, USA

Received: Nov 15, 2025

Accepted: Nov 25, 2025

Corresponding author's email:

[ikemefulaoriaku@gmail.com](mailto:ikemefulaoriaku@gmail.com)



This work is licensed under a  
Creative Commons Attribution 4.0  
International License

## Abstract

Artificial intelligence (AI) is increasingly shaping modern healthcare by enabling data-driven decision-making, improving diagnostic accuracy, and optimizing resource use. In transfusion medicine, AI offers substantial opportunities to enhance donor management, automate blood typing and compatibility testing, strengthen inventory forecasting, and support early detection of transfusion-related complications. This review summarizes current applications of AI technologies—including machine learning, deep learning, natural language processing, computer vision, and predictive analytics—and evaluates their impact across laboratory, clinical, and operational domains. Emerging innovations such as precision transfusion, patient digital twins, multi-omics integration, and federated learning highlight AI's potential to advance personalized and interconnected transfusion practices. However, successful implementation requires addressing challenges related to data heterogeneity, algorithmic bias, privacy and ethical considerations, and evolving regulatory requirements. Establishing rigorous validation standards and promoting interdisciplinary collaboration will be essential to ensure that AI improves the safety, efficiency, and sustainability of transfusion medicine.

**Keywords:** Artificial Intelligence; Machine Learning; Transfusion Medicine; Blood Safety; Predictive Analytics

## Introduction

### Background

Transfusion medicine is a support of the contemporary healthcare systems as it guarantees the provision of blood and its components to the patients in urgent demand in a safe and timely fashion [1]. About trauma resuscitation and major surgery or hematology malignancies and chronic anemias, life-saving interventions are based on transfusion practices and one simply needs to look around and almost every medical field has saved life through transfusion practices [2]. In spite of the spectacular improvements in screening of donors, removal of pathogens, and processing of components, transfusion medicine remains under some challenges of safety of blood, optimum utilization and equilibrium between the number of donors and the demand. The highly unstable and volatile character of donor supply, and the relative perishability of blood products, presents continued logistical challenges to blood banks and transfusion facilities throughout the world [3,4]. In addition, immunohematological compatibility, adverse reactions associated with the transfusion process, and a high-level quality assurance will be ineffective without constant human supervision and the resources needed to support the process.

### Why Artificial Intelligence?

Machine Learning (ML) and Deep Learning (DL) are also included in the subcategories of Artificial Intelligence (AI), as a new paradigm in healthcare is beginning to provide tools that can identify complex patterns and predictive information in large volumes of data[5]. ML algorithms allow systems to learn the past data and become better without direct programming, whereas the classes of the image recognition, natural language processing, and decision-making tasks are the most accurate in history with the usage of the DL architecture that is based on neural networks [6,7]. Within the field of medicine, AI-based applications have already improved the accuracy of diagnosis, treatment planning,

and resource allocation in an area of radiology, pathology, genomics, and critical care. The field of transfusion medicine is especially likely to positively experience the impact of integration of AI technologies because it has large repositories of clinical, laboratory, and operational data. Predictive analytics[8] are able to streamline the process of donor recruitment and retention, mechanize compatibility testing, predict blood demand, and even predict transfusion reactions- hence reinforcing safety and efficiency in transfusion chain[9].

### Rationale and Objectives

Although the AI application in healthcare is already well-investigated, there is a lack of the analysis related to the domain-specific use of AI in transfusion medicine. The peculiarities of the field in terms of its operational structure (including donor management analysis, laboratory automation, inventory organization, and taking care of patients) are such that the analytical frameworks applied to the particular field are unlike those used in other biomedical fields. The existing literature is divided, with the research being limited to specific implementations and not a holistic summary of AI and its ability to revamp the whole transfusion system.

This review is an effort at critically analyzing the current state of AI usage in transfusion medicine by identifying established uses, novel technologies and unresolved issues. This manuscript tries to establish the roadmap to the responsible and effective usage of AI in transfusion services by combining the knowledge of data science, transfusion practice, and regulatory views. Finally, we would like to point to the idea that AI, carefully used, can promote the objectives of precision transfusion, improve patient safety, and allow making data-funded decisions in the whole range of blood management.

## Methods

This manuscript was developed as a narrative review following recognized guidelines for non-systematic evidence synthesis.

### Search Strategy

A structured search was conducted using PubMed, Scopus, Web of Science, IEEE Xplore, and Google Scholar. Searches included combinations of:

"artificial intelligence" OR "machine learning" OR "deep learning" OR "natural language processing" OR "computer vision"

AND "transfusion" OR "blood bank" OR "blood typing" OR "hemovigilance" OR "donor management"

Searches covered 2010–2025, aligning with the emergence of healthcare AI.

### Eligibility Criteria

#### Inclusion:

- Peer-reviewed articles on AI applications in any part of the transfusion process
- Studies addressing donor management, laboratory automation, blood component

analysis, clinical decision support, or transfusion reaction prediction

- Review articles, technical reports, and high-quality computational studies

#### Exclusion:

- Non-peer-reviewed sources
- AI studies unrelated to transfusion workflows
- Studies focused solely on unrelated biomedical imaging or genomics

#### Study Selection and Justification

Titles and abstracts were screened for relevance. Full texts were evaluated for methodological clarity, relevance to transfusion workflows, and contribution to conceptual themes. Representative articles were selected to illustrate state-of-the-art applications and

highlight underlying principles rather than exhaustive coverage. Priority was given to studies with validated models, real-world datasets, or relevance to clinical and laboratory practice.

#### Synthesis Approach

Evidence was synthesized narratively under pre-defined domains:

1. Donor recruitment and retention
2. Laboratory automation and compatibility testing
3. Supply chain and inventory management
4. Hemovigilance and reaction prediction
5. Clinical decision support

This thematic framework ensures coherent integration and avoids fragmentation.

## Overview of AI Technologies Relevant to Transfusion Medicine

Artificial Intelligence (AI) is a series of computing methods that aim to reproduce the intellectual activities of humans including perception, learning, reasoning, and decision making. In transfusion medicine, AI can be used to derive clinically valuable information about complex datasets, such as donor demographics, serology profiles, laboratory parameters, and transfusion outcomes, to make a data-driven decision that will make transfusion and their results safer and more efficient [9,10]. Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), Computer Vision, and Predictive Decision Support Systems are the main AI paradigms applicable to the science of transfusion [8, 11]. All of them have specific methodological benefits applicable to various stages of the transfusion process.

#### Machine Learning (Supervised, Unsupervised, and Reinforcement Learning)

The first level of AI is Machine Learning that allows a system to find the statistical patterns of data and refines more and more successful forecasting.

- Classes of supervised learning algorithms Support vector machines (SVM), gradient boosting, and decision trees are commonly used in classification problems (e.g. predicting donor screenings or transfusion responses) and regression studies (e.g., predicting demand of blood products), especially in practice [12].
- The unsupervised learning of features (such as the clustering and dimensionality reduction methods) is used to find the pattern in the unlabeled data that aids in donor segmentation, risk stratification,

and detection of atypical serological behaviors [13].

- Reinforcement learning is a newer and more dynamic paradigm which allows AI systems to train on the best decision methodology via trial and error. Fine-tuning inventory management policies in real time in cases of uncertain supply-demand conditions can be obtained using reinforcement models in transfusion logistics [14].

On the whole, ML algorithms form the foundation of the majority of modern predictive and optimization tools that are already being tested in the framework of blood services and hospital transfusion systems.

#### Deep Learning and Neural Networks

Deep Learning, an objective in the ML, makes use of miscellaneous-layered artificial neural networks that can learn hierarchical illustrations of data. Such structures (especially convolutional neural networks (CNNs) and recurrent neural networks (RNNs)) have proven to perform brilliantly in not only challenging biomedical procedures. CNNs have been used in transfusion medicine in automated blood cell morphology analysis, digitized slide interpretation, and high-resolution blood typing using imaging data[15,16]. Likewise, RNN-based models have the potential to study behavior or patterns of transfusion events of a particular donor to identify abnormalities or predict utilization patterns. The ability of DL models to operate on high-volume, multimodal data (such as images, laboratory parameters, and words and text) makes them formidable transfusion informatics in the next generation[17].

**Natural Language Processing (NLP) for Donor and Patient Data**

Natural Language Processing helps computers to extract, synthesize, and understand unstructured text donor interviews, reports of adverse events, and clinical notes in electronic health records (EHRs)[18]. NLP models would help to automate the screening of donor eligibility and identify the trends in the narratives of hemovigilance, as well as apply contraindications to transfusion, hidden in a free-text medical report[19]. NLP alters unstructured narratives into usable computing datasets and hence it fills an essential gap between human communication and computational intelligence in transfusion systems.

**Computer Vision for Imaging-Based Diagnostics**

Deep neural networks are used by computer vision, in which a network analyzes and interprets the visual input. These tools can be used with automated microscopy of red cell morphology, platelet quality analysis and visualization of the insects of blood to develop contamination or hemolysis. Moreover, exactly the imaging systems, which are enhanced with AI, per-

mit automated blood typing and cross-matching, decreasing the likelihood of the human error and enhancing throughput in large-scale testing settings. Combining computer vision to the automation networks of the laboratories is therefore of significant potential in terms of quality assurance and accurate diagnostics[20].

**Predictive Analytics and Decision Support Systems**

Predictive is a type of analytics and it combines multiple AI solutions to detect trends, make predictions and aid in clinical or operational decision-making. Through application AI, decision support systems (DSS) can combine donor data, inventory measures and patient transfusion histories to deliver real-time suggestions of the best allocations or transfusion limits of components. Applying algorithmic prescribed intelligence to clinical guidelines, AI-based DSSs can assists in increasing consistency, minimize wastage, and facilitate evidence-based transfusion. Table 1 provides a description of the main AI methods and their exemplary applications in the context of transfusion medicine, outlining their main principles and possible effects on safety and work efficiency.

Table 1. AI Techniques and Their Relevance in Transfusion Medicine			
AI Technique	Core Principle	Representative Applications in Transfusion Medicine	Potential Impact
Supervised Machine Learning	Learns from labeled data to predict outcomes	Donor eligibility prediction, transfusion reaction classification, blood demand forecasting	Improved safety and operational efficiency[12]
Unsupervised Machine Learning	Identifies hidden structures in unlabeled data	Donor segmentation, anomaly detection, serological pattern recognition	Enhanced risk stratification and process optimization[13]
Reinforcement Learning	Learns through feedback to optimize actions	Dynamic inventory and supply chain management	Reduced wastage, optimized stock levels[14]
Deep Learning (CNN, RNN)	Multilayer neural networks learn complex, hierarchical patterns	Image-based blood typing, morphological analysis, transfusion event prediction	Automation, accuracy, and scalability[17]
Natural Language Processing (NLP)	Extracts structured meaning from text	Donor interview analysis, hemovigilance reporting, clinical note mining	Improved surveillance and data integration[11]
Computer Vision	Automated visual interpretation via image analysis	Quality control of blood products, automated microscopy	Enhanced laboratory precision and throughput[21]

AI Technique	Core Principle	Representative Applications in Transfusion Medicine	Potential Impact
Predictive Analytics / DSS	Synthesizes data to guide decisions	Personalized transfusion triggers, inventory control, utilization review	Data-driven decision-making and precision transfusion[8]

Current Applications of AI in Transfusion Medicine

The recent adoption of Artificial Intelligence (AI) throughout the transfusion medicine spectrum, including the recruitment and recruitment of donors to the post-transfusion follow-up, has provided a new horizon of effectiveness, accuracy, and safety. The subsequent subsections are used to describe significant areas in which AI tools have already proven to be of clinical and operational value.

The applications described in this section represent AI tools that have been implemented, clinically piloted, or validated using real-world transfusion data. These technologies are currently in use within transfusion workflows or have demonstrated practical feasibility in laboratory or clinical environments. In contrast, Section 5 focuses exclusively on emerging or experimental approaches that remain in developmental stages, conceptual research, or early proof-of-concept designs.

Donor Recruitment and Retention

The issue of recruiting and retaining trustworthy blood donors has been a focal point in transfusion medicine, especially in areas where there is a variation in donors or where there is a demographic change. The application of machine learning (ML) algorithms under predictive modeling allowed identifying the factors affecting the eligibility of donors, their repeated use of donations, and their likelihood to receive deferrals. Predictive systems can be used to determine which donors will be most successful on returning or lapsing based on historical data on donation and trends in their behavior, as well as socio-demographic factors[8,10,22].

Moreover, sentiment analysis and custom closing models that will be based on the implementation of Natural Language Processing (NLP) to survey responses and feedback forms and the work with social networks will enable the blood services to customize communication processes that contribute to increased satisfaction and commitment of donors. Such insights based on data can make the supply system more sustainable and donor-centric[11].

Blood Typing and Compatibility Testing

Widely used in the deployment of computer vision and deep learning techniques, AI has transformed

serological and molecular compatibility testing. The convolutional neural networks (CNNs) can effectively process images of agglutination reactions or gel-card assays at high resolution and deliver accurate and repeatable blood typing without any bias in scoring that is associated with manual reading.

In addition, automated cross-matching systems are now compatible with AI algorithms that can interpret more complicated serological data and anticipate possible incompatibilities between the sample of the donor and recipient. The systems accelerate laboratory processing and reduce the role of human error, which is complemented by the completely automated, AI-powered compatibility processes that can meet quality requirements set by regulatory bodies[23,24].

Blood Supply Chain and Inventory Management

The management of blood inventories is very important in balancing supply and demand as well as reducing news wastage. The demand forecasting model constructed by an AI can be used to predict blood usage patterns based on the historical transfusion rates, hospital admission rates, and seasonal factors[25]. Frequently, time-series ML algorithms, including recurrent neural networks (RNNs), are used to construct the demand forecasting model.

Such predictive insights make it possible to optimize a dynamic stock, so that in time, the blood centers will be able to make changes to a collection schedule and distribution plans. Reinforcement learning systems also contribute to improving agility of a supply chain by modeling uncertainties of the real world (e.g., donor turnout, emergency surges) and proposing responses to the changes. Under predictive logistics, AI systems assist in cost efficiency, as well as transfusion safety, which is important since essential parts should be where they are most needed and when needed[26].

Transfusion Reaction Prediction and Hemovigilance

AI has great potential in the context of hemovigilance as it involves a transition to a more proactive rather than passive surveillance rather than reactive risk prediction. Patients who are at high risk of developing



complications associated with transfusion, including Transfusion-Related Acute Lung Injury (TRALI) or Transfusion-Associated Circulatory Overload (TACO) are identified by machine learning classifiers trained using large-scale datasets of transfusion records, patient characteristics and lab results [10].

Furthermore, NLP-based AI-driven surveillance systems can automatically identify and analyze adverse narratives of incidents and extract them automatically, using electronic health records (EHRs), incident reporting, and free-text documentation. These systems do not only speed up the process of identifying the signals on safety but also increase uniformity in adverse event coding and reporting, which strengthens the credibility of both national and international hemovigilance programs[27].

### **Quality Control and Laboratory Automation**

The implementation of computer vision and AI systems with the assistance of robots in transfusion laboratories is altering quality control (QC). Deep learning models can be used to automate red blood cell morphology analysis, platelet clumping, and leukocyte contamination analysis, which require human hands before[28].

In addition to decoding images, AI technology can be used to do real-time authenticity of test runs, reagent stability, temperature changes, and instrument calibration to indicate discrepancy before it causes quality deterioration. The outcome is a closed lab ecosystem that is more precise, has an improved level of traceability, and satisfies regulatory standards including ISO 15189 [29].


### **Clinical Decision Support Systems**

Clinical decision support systems AI-based programs are being developed as essential aids in the direction of transfusion practice occurring at the point of

care. These systems can provide personalized work based on the current trends and comorbidities in patients, as well as the information in the EHR used to come up with personalized transfusion orders that have been checked against existing clinical guidelines[30].

The state-of-the-art CDSS systems embrace predictive analytics to detect at-risk patients facing either an over- or under-transfusion risk, prescribe optimal transfusion parameters, and support patient blood management (PBM) plans. Combined with the supervision of clinicians, AI-powered decision systems bring about better suitability and timeliness of transfusion, which are critical factors in patient outcomes and resource management[30]. There is a conceptual map (Figure 1) that shows that the integration of AI throughout the transfusion process can support every step of the process, including donor recruitment, and post-transfusion surveillance by means of data-driven intelligence.

Taken together, the existing applications of AI show a clear shift from manual, reactive transfusion practices toward automated and predictive systems. Across donor management, laboratory testing, supply chain forecasting, hemovigilance, and clinical decision support, a consistent pattern emerges: AI enhances accuracy, reduces human-related variability, and provides earlier insight into risks or needs. Although each domain has developed its tools independently, the collective evidence demonstrates convergence toward a more integrated, data-driven transfusion ecosystem. These findings suggest that the greatest gains occur when AI models interact across the full transfusion chain—linking donor behavior, laboratory quality, utilization patterns, and patient outcomes into a unified workflow that continuously improves through feedback.



**Figure 1. Integration of Artificial Intelligence Across the Transfusion Medicine Continuum.** AI-supported workflow in transfusion medicine, highlighting its role

in donor screening, laboratory testing, inventory management, and clinical decision-making. Figure created by the authors for this manuscript.

## Opportunities and Future Directions

The convergence between Artificial Intelligence (AI) and transfusion medicine foreshadows the transformative possibilities that are so immense that they go beyond existing implementations. The growing computing power, accompanied by more and more rich biomedical data, has led to new paradigms that will result in finer workmanship, increased safety, and better operational efficiency in transfusion services. This section discusses the most promising frontiers on which the AI innovation could transform the field. Some of the emerging opportunities that can change transfusion medicine through the improved personalization, real-time analytics, and secure data collaboration are presented in Table 2. The following technologies represent innovations that are not yet widely deployed in transfusion medicine but show strong potential based on ongoing research, early prototypes, or experimental data.

### Precision Transfusion: Personalized Donor-Recipient Matching

The current transfusion approaches are based primarily on ABO and Rh compatibility, with additional antigen matching conducted to meet the unique needs of specific patient groups. One of the areas AI can contribute to is changing the paradigm of precision transfusion based on the combination of complex immunohematological profiles, the genetics of donors, and the immune status of recipients. Big datasets containing small antigen variants and alloimmunization history

can be analyzed by machine learning algorithms that will enable individual donor-recipient matching, curbing alloimmune disease complications, and maximizing the effectiveness of transfusion. These customized measures are specifically applicable in chronically transfused patients, such as those who have sickle cell disease or thalassemia, in which immune sensitization is a highly relevant factor that can influence clinical outcome[9,31].

### Digital Twins: Modeling Patient Transfusion Responses

Digital twins, which are virtual, computational analogs of biological systems, present a simulation of the response of individual patients to transfusion therapies with unprecedented opportunities. With the help of these supplies of multi-dimensional patient data, such as physiological parameters, laboratory results, and transfusion history analysis, AI-driven digital twins identify hemoglobin kinetics, transfusion efficacy, and risk of indicating adverse events. Such models can be used to conduct experiments in silico, with clinicians experimenting with various transfusion strategies before clinical use and, therefore, optimizing the pathways of patient-specific care and resource use[32,33].

### Integration with Genomics and Proteomics

Recent studies have identified that genomic and proteomic contributors play a crucial role in dictating the outcomes of transfusion, i.e., whether an organism

will lose the transfusion by acting as an alloimmunophenotype or respond in an unpredictable manner to blood constituents. Multi-omics datasets can be combined with clinical and laboratory data to identify multi-omics relationships, which can be used to explain complex biomolecular interactions that mediate transfusion biology, through AI techniques. Clinically, AI integration with systems biology is potentially beneficial in discovering new biomarkers, improving risk stratification, and eventually providing omics-based approaches to transfusion that go beyond the previous serological training[34].

**Real-Time Analytics in Emergency Transfusion Services**

Timely and correct transfusion decisions are important in the emergency clinical situation, like in a trauma or in case of great losses. Radical artificial intelligence (AI) can be used to tailor dynamic recommendations by real-time analytics systems based on streaming data at bedside, lab, and hospital information systems to deliver context-sensitive transfusion instructions. These systems enhance fast triage, mobilization of

inventory, and optimum dosage, minimize delays, and enhance results in high-stakes settings. AI implementation of emergency transfusion processes is a decisive move towards adaptive data-driven models of acute care[30].

**Federated Learning for Multi-Center AI Model Training**

The lack of data privacy and security is a significant obstacle to merging patient-level data across institutions to develop an AI model. Federated learning systems present a remedy in that decentralized training of AI models is possible based on local datasets, without any data exchange. Such a practice would contribute to the collective model development of blood centers and hospitals, but would not reveal data to third parties and satisfy the requirements of regulatory requirements like GDPR and HIPAA. Federated learning, therefore, enhances the production of a powerful, generalizable artificial intelligence framework that represents varied patient groups and transfusion habits[35].

Opportunity	Description	Potential Impact
Precision Transfusion	AI-driven personalized donor–recipient matching using immunohematological and genetic data	Reduced alloimmunization, improved transfusion efficacy[9,10]
Digital Twins	Virtual patient models simulating transfusion responses and outcomes	Optimized patient-specific transfusion strategies[32]
Genomics and Proteomics Integration	Multi-omics data fusion for biomarker discovery and risk stratification	Enhanced understanding of transfusion biology and personalized care[36]
Real-Time Emergency Analytics	AI platforms providing dynamic transfusion decision support during acute care and hemorrhage management.	Improved response times and patient survival in emergencies[10]
Federated Learning	Decentralized AI model training across centers, preserving data privacy	Collaborative, scalable AI models with broad applicability[35]

This is a promising new field of future research and clinical innovation. Nonetheless, it will need a multidisciplinary teamwork strategy, intensive validation, and ethical guardianship to change these opportunities into an everyday routine in order to make AI tools effective and fair.

Collectively, these emerging innovations signal a transition from AI as a supportive operational tool to AI as a central component of personalized transfusion medicine. Precision matching, digital twins, multi-omics integration, real-time analytics, and federated learning all build on one another: each technology addresses

limitations of current systems while enabling richer, more individualized datasets. The synthesis of these developments suggests that the future of transfusion medicine lies in interoperable platforms capable of learning across institutions, predicting needs before they arise, and tailoring transfusion strategies to each patient. Together, these opportunities highlight a pathway toward a more adaptive, precise, and equitable transfusion ecosystem. *Federated learning is particularly valuable for rare blood types, where individual centers lack sufficient cases for model training; distributed learning enables the creation of*



*robust, generalizable algorithms without compromising data privacy.*

## Challenges and Limitations

The potential of Artificial Intelligence (AI) in the field of transfusion medicine as the change is great, yet there are a number of essential challenges and limitations that hinder its popularization. All these challenges cut across technical, ethical, regulatory, and operational planes, which means that an integrated approach to the implementation of AI must be measured and interdisciplinary. The discussion of the most important technical, ethical, and regulatory obstacles to AI integration in transfusion medicine is outlined in Figure 2, highlighting the nature of their interdependence and influence on the implementation.

### Data Challenges

The quality of data and its accessibility are still considered the groundbreaking obstacles to the creation of reliable AI systems in the sphere of transfusion medicine. The existence of heterogeneity in the data formats, sources, and quality will lead to incomplete and inconsistent datasets that will compromise the model's robustness. As an example, variable granularity and accuracy in donor records, laboratory findings, and transfusion outcomes may exist between institutions, which will make it more difficult to harmonize data to draw a conclusion. Additionally, these biases given by historical data can spread to AI models, reinforcing inequities due to their demographic and underrepresentation, as well as the biases in various institutional activities. Multicenter model development and external validation are further limited by the paucity of standardized and interoperable datasets, as well as a small number of data sharing agreements[20].

### Ethical and Legal Considerations

There are intricate ethical and legal regulations of patient and donor information that AI applications used in transfusion medicine have to bypass. Legal standards that govern data privacy, such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in Europe, may require very high security measures to ensure that sensitive health information is safeguarded. In addition to the privacy issue, the unfairness of the algorithm and biases will also be an issue because AI models may have dissimilar effects in influencing donor or patient subgroups that can lead to the exclusion of individuals unfairly or negatively. It is critical to safeguard ethical integrity and ensure the populace trusts AI-based advanced technologies, as this

requires becoming open through reporting the criteria of AI decision-making and regularly monitoring any discriminatory consequences [9].

### Technical Barriers

One technical challenge to the application of AI is that most machine learning and deep learning models are black boxes, and therefore, their decision-making processes are not transparent. This explainability is restricted, and thus makes AI recommendations less acceptable by clinicians, regulators, and the auditability of adversarial transfusion recommendations. Moreover, the introduction of AI tools in the current clinical systems, such as Laboratory Information Systems (LIS) and Electronic Health Records (EHR), is usually characterized by interoperability problems, workflow issues, and unstable IT infrastructure. To overcome these technical vagaries, there is a need to search for a solid software engineering effort, standardization of data exchange protocols, and user-focused design to support a smooth adoption [37].

Beyond the technical and regulatory barriers, real-world implementation of AI systems in transfusion medicine also depends on operational readiness. Successful adoption requires a workforce trained in digital literacy, quality oversight of algorithm performance, and collaboration between laboratory scientists, clinicians, informaticians, and IT engineers. Integration timelines typically include phases of model validation, sandbox testing, phased rollout, and ongoing monitoring to identify performance drift. Infrastructure requirements such as interoperable LIS/EHR systems, secure data storage, high-performance computing capabilities, and robust cybersecurity protocols also influence feasibility. These factors collectively determine the pace and sustainability of AI integration within transfusion services.

### Regulatory and Implementation Barriers

Regulatory bodies like the U.S Food and Drug Administration (FDA) and European Medicines Agency (EMA) are already starting to offer frameworks of regulation of AI-enabled medical equipment and decision support systems, but regulatory frameworks are still developing and complicated. Compliance is complicated by the fact that there is no well-defined procedure on how to approve adaptive AI models, which would keep learning even after deployment. In addi-

tion, its implementation is associated with high monetary expenses in acquiring technology, maintaining it, and training employees. The cultural factors of restraining change, the inability of healthcare providers to utilize AI, and the issues of liability are additional obstacles to the universal implementation. These complex barriers will require a collaborative action on the part of policymakers, healthcare leaders, and technology developers[38].

Overall, the challenges identified across data quality, ethics, technical infrastructure, and regulatory

pathways are deeply interconnected. Data heterogeneity leads to algorithmic bias; privacy regulations complicate data sharing; lack of transparency reduces clinician trust; and evolving regulatory frameworks hinder the deployment of adaptive models. This synthesis shows that barriers cannot be addressed in isolation—successful AI adoption will require coordinated action across technological, institutional, and policy levels. The collective evidence underscores that the primary limitation is not the AI tools themselves, but the ecosystem needed to support their safe, fair, and reliable use in transfusion medicine.



**Figure 2.** Key barriers to implementing artificial intelligence in transfusion medicine include data heterogeneity, privacy and ethical concerns, technical limitations, and regulatory challenges.

## Recommendations and Framework for Safe AI Integration

In order to realize the transformative power of Artificial Intelligence (AI) in transfusion medicine and counteract the risks involved, the creation of a coherent framework of governance, validation, and implementation is inevitable. This framework should include technical rigor, ethical, and multidisciplinary coordination so that AI systems might be secure, efficient, and fair.

### Governance and Validation Framework

A major aspect of responsible AI implementation is the development of a standardized protocol to develop and test models and monitor them. Pre-deployment testing of AI algorithms requires thorough evaluation using

both retrospective testing of multicenter datasets and assessments of generalizability and bias in AI algorithms. After its deployment, it is important to monitor the real-world performance regularly and through regular recalibration to monitor the drift of models and to ensure the accuracy. The regulatory agencies and professional societies ought to discuss the benchmark standards and certification opportunities with respect to the AI application in transfusion medicine, with clear guidelines on transparency and risk management [39].

### Interdisciplinary Collaboration

The integration of AI requires the unified effort of clinicians, data scientists, bioinformaticians, ethicists, and regulators, because of its high complexity. Having the right clinical domain knowledge, clinicians put AI products into the proper context by using the results of patient treatment pathways and make sure that it is clinically relevant and safe. Algorithms and optimization of the system are brought in by data scientists and engineers. Ethicists and legal practitioners inform infrastructures on privacy, fairness, and accountability, and regulators enforce adherence to the changing policies. Interdisciplinary teams such as these enable an iterative co-design of work, enabling a focus on usability, transparency, and clinician trust, which are principal influences of successful adoption [40].

### Emphasis on Transparency, Reproducibility, and Accountability

Clinician confidence, as well as regulatory approval, can be achieved through transparency of AI decision-making processes. Model predictions can be demystified by applying explainable AI (XAI) techniques to allow users to tailor to the end-users to query and understand the output. In addition, it requires the reproducibility of the code, methodologies, and datasets wherever feasible, enhancing the external validation and community confidence. The understanding of accountability should be established to explain the responsibility of AI-

driven clinical decisions, such as the fact that model limitations need to be documented and that plans against contingencies that may lead to human regulation should be stated. This three-part plan of transparency, reproducibility, and accountability is used as an ethical basis of AI implementation in transfusion medicine[41].

With these recommendations in place, the community of transfusion medicine will be able to have a robust, dynamic ecosystem in which AI becomes a welcome collaborator, which will make it easier to form clinical decisions, resources, and eventually enhance patient outcomes.

### Data Harmonization Across Institutions

*Because data heterogeneity remains a major barrier to reliable AI development, harmonizing transfusion-related data across institutions is essential. Standardized terminologies—such as ISBT 128 coding for blood components and SNOMED CT for clinical transfusion events—can reduce variability in data definitions. Establishing a minimum transfusion dataset, including donor characteristics, laboratory parameters, and outcome metrics, facilitates multicenter validation. Interoperability can be strengthened by aligning LIS and EHR interfaces through common data models and standardized exchange formats (e.g., HL7 FHIR). Regulatory frameworks that support secure data transfer, including federated learning networks compliant with GDPR or HIPAA, also enable collaborative model development without requiring direct data sharing. Together, these strategies create a more uniform and scalable foundation for AI adoption in transfusion medicine.*

## Conclusion

Artificial intelligence is becoming an important driver of progress in transfusion medicine. Across donor management, laboratory testing, supply chain forecasting, hemovigilance, and clinical decision support, the available evidence shows a clear pattern of improvement in accuracy, consistency, and early identification of risks. These developments indicate a gradual shift from manual and reactive workflows to approaches that are more predictive and data-informed.

Future opportunities such as precision transfusion, digital twins, multi-omics integration, real-time analytics, and federated learning point toward a more personalized and interconnected transfusion system. These emerging fields build on existing successes and suggest that the greatest future gains will come from platforms that integrate clinical, laboratory, operational, and biological data to guide decision making.

At the same time, significant challenges remain. Data heterogeneity, privacy concerns, algorithmic bias,

limited transparency, and uncertain regulatory pathways influence one another and can restrict adoption. These issues show that successful implementation depends on improvements in technical infrastructure, institutional readiness, governance, and ethical oversight.

Taken together, the findings of this review show a field with strong potential for transformation. Artificial intelligence has already demonstrated meaningful benefits, but its full impact will depend on coordinated investment in validation, collaboration, and responsible integration. With these elements in place, artificial intelligence can support a safer, more efficient, and more patient-centered transfusion environment.

## Acknowledgements

**Author Contributions:** Ikemefula Oriaku conceptualized the review, led the manuscript design, and coordinated writing. Oluchi Okechukwu contributed to methodology development, literature evaluation, and critical revision of clinical and laboratory sections. Obiageri Ihuarulam Okeoma participated in data curation, thematic synthesis, and drafting of laboratory automation content. Chidinma Gab-Obinna contributed to the sections on AI technologies, computer vision, and quality assurance. Jazuli Isyaku Bala provided expertise on transfusion medicine operations and contributed to supply chain and hemovigilance sections. Adeyinka Moyinoluwa Adejumobi contributed to the AI technical framework, including machine learning,

deep learning, and predictive modeling. Oluwabusayo Olufunke Awoyomi provided expertise in data science, NLP, and emerging AI opportunities, and assisted in manuscript editing. All authors reviewed and approved the final manuscript

**Disclosures:** The authors declare no conflicts of interest related to the development, analysis, or publication of this manuscript. No commercial or financial relationships influenced the content of this review.

**Funding:** This research received no external funding. The work was conducted independently by the authors without support from governmental, commercial, or nonprofit funding agencies.

## References

1. Yadav SK, Hussein G, Liu B, Vojjala N, Warsame M, Labban ME, et al. A Contemporary Review of Blood Transfusion in Critically Ill Patients. *Medicina* [Internet]. 2024 Jul 30;60(8). Available from: <https://doi.org/10.3390/medicina60081247>
2. Knowles C, Raitt J. Blood transfusion – moving from what to how. *Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine*. 2025 Jul 6;33(1):118. Available from: <https://doi.org/10.1186/s13049-025-01300-9>
3. Lotterman S, Sharma S. Blood Transfusion. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Nov 13]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK499824/>
4. Coccolini F, Shander A, Ceresoli M, Moore E, Tian B, Parini D, et al. Strategies to prevent blood loss and reduce transfusion in emergency general surgery, WSES-AAST consensus paper. *World Journal of Emergency Surgery*. 2024 Jul 16;19(1):26. Available from: <https://doi.org/10.1186/s13017-024-00553-8>
5. Razzaq K, Shah M, Razzaq K, Shah M. Machine Learning and Deep Learning Paradigms: From Techniques to Practical Applications and Research Frontiers. *Computers* [Internet]. 2025 Mar 5;14(3). Available from: <https://doi.org/10.3390/computers14030093>
6. Nagpure N, Raut H, Kamble S, Rasala T. Redefining Preclinical Research Paradigms: AI-Driven Drug Discovery as a Transformative Approach to Accelerate Innovation, Improve Predictive Accuracy, and Reduce Reliance on Animal Testing. *Journal of Drug Delivery and Therapeutics*. 2025 Oct 15;15(10):115–28. Available from: <https://doi.org/10.22270/jddt.v15i10.6804>
7. Mohamed N. Artificial intelligence and machine learning in cybersecurity: a deep dive into state-of-the-art techniques and future paradigms. *Knowl Inf Syst*. 2025 Aug 1;67(8):6969–7055. Available from: <https://doi.org/10.1007/s10115-025-02238-5>
8. Animashaun TA, Sunday O, Ogunleye E, Agbahiwe OK, Afolayan ON, Okpoko OA, et al. AI-Powered Digital Twin Platforms for Next-Generation Structural Health



- Monitoring: From Concept to Intelligent Decision-Making. *Journal of Engineering Research and Reports*. 2025 Sep 22;27(10):12–37. Available from: <https://doi.org/10.9734/jerr/2025/v27i101344>
9. Cognasse F, Avril S, Fleck JL, Hamzeh-Cognasse H. Artificial Intelligence in transfusion medicine: a paradigm shift on the horizon. *Blood Transfusion*. 2025 Aug 4;23(6):558. Available from: <https://doi.org/10.2450/bloodtransfus.777>
  10. Barzilai M, Cohen O. AI Applications in Transfusion Medicine: Opportunities, Challenges, and Future Directions. *Acta Haematol*. 2025 May 9;1–11. Available from: <https://doi.org/10.1159/000542158>
  11. Okayo OD, Panwal NE, Ihuarulam OO, Nzunde MS, Nyimwadang FA, Oladosu TA, et al. Transforming Medical Laboratory Science with Vision-Language Models: A Focus on Microscopy in Microbiology, Hematology, and Histopathology. *Oncology, Nuclear Medicine, and Transplantology*. 2025 Oct 21;1(2):onmt008. Available from: <https://doi.org/10.1093/onmt/onmt008>
  12. Owess MM, Owda AY, Owda M, Massad S, Owess MM, Owda AY, et al. Supervised Machine Learning-Based Models for Predicting Raised Blood Sugar. *International Journal of Environmental Research and Public Health* [Internet]. 2024 Jun 26;21(7). Available from: <https://doi.org/10.3390/ijerph21070840>
  13. Jacokes Z, Adoremos I, Hussain AR, Newman BT, Pelphrey KA, Van Horn JD. Unsupervised Dimensionality Reduction Techniques for the Assessment of ASD Biomarkers. *Pac Symp Biocomput*. 2025;30:614–30. Available from: [https://doi.org/10.1142/9789811283780\\_0056](https://doi.org/10.1142/9789811283780_0056)
  14. Wu Q, Han J, Yan Y, Kuo YH, Shen ZJM. Reinforcement learning for healthcare operations management: methodological framework, recent developments, and future research directions. *Health Care Manag Sci*. 2025;28(2):298–333. Available from: <https://doi.org/10.1007/s10729-024-09685-4>
  15. Li M, Jiang Y, Zhang Y, Zhu H. Medical image analysis using deep learning algorithms. *Front Public Health*. 2023 Nov 7;11:1273253. Available from: <https://doi.org/10.3389/fpubh.2023.1273253>
  16. Mienye ID, Swart TG, Mienye ID, Swart TG. A Comprehensive Review of Deep Learning: Architectures, Recent Advances, and Applications. *Information* [Internet]. 2024 Nov 26;15(12). Available from: <https://doi.org/10.3390/info15120755>
  17. Kim JC, Chung K, Kim JC, Chung K. Recurrent Neural Network-Based Multimodal Deep Learning for Estimating Missing Values in Healthcare. *Applied Sciences* [Internet]. 2022 Jul 25;12(15). Available from: <https://doi.org/10.3390/app12157477>
  18. Wieland-Jorna Y, van Kooten D, Verheij RA, de Man Y, Francke AL, Oosterveld-Vlug MG. Natural language processing systems for extracting information from electronic health records about activities of daily living. A systematic review. *JAMIA Open*. 2024 May 24;7(2):ooae044. Available from: <https://doi.org/10.1093/jamiaopen/ooae044>
  19. Golder S, Xu D, O'Connor K, Wang Y, Batra M, Hernandez GG. Leveraging Natural Language Processing and Machine Learning Methods for Adverse Drug Event Detection in Electronic Health/Medical Records: A Scoping Review. *Drug Saf*. 2025;48(4):321–37. Available from: <https://doi.org/10.1007/s40264-024-01486-6>
  20. Lopes MGM, Recktenwald SM, Simionato G, Eichler H, Wagner C, Quint S, et al. Big Data in Transfusion Medicine and Artificial Intelligence Analysis for Red Blood Cell Quality Control. *Transfus Med Hemother*. 2023 May 25;50(3):163–73. Available from: <https://doi.org/10.1159/000530656>
  21. Campos-Medina M, Blumer A, Kraus-Füederer P, Mayrhofer-Reinhartshuber M, Kainz P, Schmid JA, et al. AI-Enhanced Blood Cell Recognition and Analysis: Advancing Traditional Microscopy with the Web-Based Platform IKOSA. *Journal of Molecular Pathology*. 2024 Jan 24;5(1):28–44. Available from: <https://doi.org/10.3390/jmp5010003>



22. Lawal OP, Igwe EP, Olosunde A, Chisom EP, Okeh DU, Olowookere AK, et al. Integrating Real-Time Data and Machine Learning in Predicting Infectious Disease Outbreaks: Enhancing Response Strategies in Sub-Saharan Africa. *Asian Journal of Microbiology and Biotechnology*. 2025 May;10(1):147–63. Available from: <https://doi.org/10.53568/AJMB2025-10-01-15>
23. Dewaker V, Morya VK, Kim YH, Park ST, Kim HS, Koh YH. Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools. *Biomarker Research*. 2025 Mar 29;13(1):52. Available from: <https://doi.org/10.1186/s40364-025-00641-0>
24. Gedefaw L, Liu CF, Ip RKL, Tse HF, Yeung MHY, Yip SP, et al. Artificial Intelligence-Assisted Diagnostic Cytology and Genomic Testing for Hematologic Disorders. *Cells*. 2023 Jun 30;12(13):1755. Available from: <https://doi.org/10.3390/cells12131755>
25. Elmir WB, Hemmak A, Senouci B, Elmir WB, Hemmak A, Senouci B. Smart Platform for Data Blood Bank Management: Forecasting Demand in Blood Supply Chain Using Machine Learning. *Information* [Internet]. 2023 Jan 4;14(1). Available from: <https://doi.org/10.3390/info14010031>
26. Zhang Y, He L, Zheng J, Zhang Y, He L, Zheng J. A Deep Reinforcement Learning-Based Dynamic Replenishment Approach for Multi-Echelon Inventory Considering Cost Optimization. *Electronics* [Internet]. 2024 Dec 26;14(1). Available from: <https://doi.org/10.3390/electronics14010066>
27. Lawal O, Oyebamiji HO, Kelenna IJ, Chioma FJ, Oyefeso E, Adeyemi BI, et al. A Review on Usage of Digital Health Literacy to Combat Antibiotic Misuse and Misinformation in Nigeria: Review Article. *Journal of Pharma Insights and Research*. 2025 Apr 5;3(2):258–69. Available from: <https://doi.org/10.69945/jopir.2025.3.2.258-269>
28. Naouali S, El Othmani O. AI-Driven Automated Blood Cell Anomaly Detection: Enhancing Diagnostics and Telehealth in Hematology. *J Imaging*. 2025 May 16;11(5):157. Available from: <https://doi.org/10.3390/jimaging11050157>
29. Shin Y, Lee M, Lee Y, Kim K, Kim T, Shin Y, et al. Artificial Intelligence-Powered Quality Assurance: Transforming Diagnostics, Surgery, and Patient Care—Innovations, Limitations, and Future Directions. *Life* [Internet]. 2025 Apr 15;15(4). Available from: <https://doi.org/10.3390/life15040654>
30. ShojaeiBaghini M, Ghaemi MM, Ahmadipour A. Artificial intelligence in the identification and prediction of adverse transfusion reactions(ATRs) and implications for clinical management: a systematic review of models and applications. *BMC Med Inform Decis Mak*. 2025 Oct 28;25:396. Available from: <https://doi.org/10.1186/s12911-025-02852-x>
31. Park I, Jang WS, Lim CS, Kim J, Park I, Jang WS, et al. Evaluation of Pre-Transfusion Crossmatch Test Using Microscanner C3. *Diagnostics* [Internet]. 2024 Jun 11;14(12). Available from: <https://doi.org/10.3390/diagnostics14121231>
32. Saratkar SY, Langote M, Kumar P, Gote P, Weeraratna IN, Mishra GV. Digital twin for personalized medicine development. *Front Digit Health*. 2025 Aug 7;7:1583466. Available from: <https://doi.org/10.3389/fdgth.2025.1583466>
33. Enabulele ABO, Eleweke CC, Okechukwu O, Akanbi OO, Majesty C. A Strategic Project Management Framework for Implementing Patient-Centered Digital Health Record Systems to Improve Chronic Disease Outcomes in the United States. *Journal of Sustainable Research and Development*. 2025 Nov 13;1(2):55–67. Available from: <https://doi.org/10.69793/01.01.2025.055067>
34. Ikwelle TA, Ihim AC, Ozuruoke DFN, Obi PC, Obi CU, Onuora IJ, et al. Multi-Omics Integration in Personalized Medicine: Advancing Laboratory Diagnostics and Precision Therapeutics in the Era of Individualized Healthcare. *Journal of Drug Delivery and Therapeutics*. 2025 May

- 15;15(5):132–42. Available from: <https://doi.org/10.22270/jddt.v15i5.6779>
35. Zhan S, Huang L, Luo G, Zheng S, Gao Z, Chao HC, et al. A Review on Federated Learning Architectures for Privacy-Preserving AI: Lightweight and Secure Cloud–Edge–End Collaboration. *Electronics* [Internet]. 2025 Jun 19;14(13). Available from: <https://doi.org/10.3390/electronics14132512>
  36. Lin M, Guo J, Gu Z, Tang W, Tao H, You S, et al. Machine learning and multi-omics integration: advancing cardiovascular translational research and clinical practice. *Journal of Translational Medicine*. 2025 Apr 2;23(1):388. Available from: <https://doi.org/10.1186/s12967-025-05806-1>
  37. Ahangar MN, Farhat ZA, Sivanathan A, Ahangar MN, Farhat ZA, Sivanathan A. AI Trustworthiness in Manufacturing: Challenges, Toolkits, and the Path to Industry 5.0. *Sensors* [Internet]. 2025 Jul 10;25(14). Available from: <https://doi.org/10.3390/s25144357>
  38. Singh R, Zhou K, Auclair JR. Reimagining drug regulation in the age of AI: a framework for the AI-enabled Ecosystem for Therapeutics. *Front Med (Lausanne)*. 2025 Oct 16;12:1679611. Available from: <https://doi.org/10.3389/fmed.2025.1679611>
  39. Rabbani SA, El-Tanani M, Sharma S, Rabbani SS, El-Tanani Y, Kumar R, et al. Generative Artificial Intelligence in Healthcare: Applications, Implementation Challenges, and Future Directions. *BioMedInformatics* [Internet]. 2025 Jul 6;5(3). Available from: <https://doi.org/10.3390/biomedinformatics5030037>
  40. Singh MP, Keche YN. Ethical Integration of Artificial Intelligence in Healthcare: Narrative Review of Global Challenges and Strategic Solutions. *Cureus*. 2025;17(5):e84804. Available from: <https://doi.org/10.7759/cureus.84804>
  41. Abbas Q, Jeong W, Lee SW. Explainable AI in Clinical Decision Support Systems: A Meta-Analysis of Methods, Applications, and Usability Challenges. *Healthcare (Basel)*. 2025 Aug 29;13(17):2154. Available from: <https://doi.org/10.3390/healthcare13172154>